June L. Biedler, Barbara A. Spengler, Lawrence Helson
Memorial Sloan-Kettering Cancer Center (MSK)
SKU:
161936
Product description:
SK-N-MC was originally described as a neuroblastoma cell line. It is now widely regarded as having originated from an Askin’s tumour (Ewing family of tumours).
Gender:
Female
Products or characteristics of interest:
Karyotype: The cell line is a pseudodiploid human female (XX), with chromosome counts in the diploid range and a modal chromosome number of 46. Normal chromosomes N3 and N10 are absent, and many (N1, N2, N4, N15, N16, N17, N21, and N22) are monosomic. Normal chromosome N8 is most often tetrasomic. The remainder of normal chromosomes were usually paired. Numerous marker chromosomes are present including: 1p+, der(3)t(2;3)(q24;q27), del(4)(p12), 11q+, del(2)(q23), ampl.(17)(p12), ampl.(16)(q13), del(15)(q13q22), 21p+, iso(3q), del(22)(q11q13). Marker chromosomes M2 and M3 appear to us to be identical to two markers (M4 and M3, respectively) described by R.C. Seeger, et al.for this cell line. Isoenzymes: AK-1, 1 ES-D, 2 G6PD, B GLO-I, 1-2 Me-2, 2 PGM1, 1 PGM3, 1-2
Cat. #:
161936
Cancer types:
Neuroblastoma
Tissue:
Brain
Gender:
Female
Morphology:
Epithelial
Growth properties:
Adherent
Cancer Types In Detail:
Neuroblastoma
Primary citation:
Biedler et al. Cancer research. 1973. 33(11):2643-2652. PMID: 4748425.
Shipping conditions:
Dry Ice
Growth medium:
1:1 mixture of ATCC-formulated Eagle’s Minimum Essential Medium, Catalog No. 30-2003, and F12 Medium then supplemented with fetal bovine serum to a final concentration of 10%.
Temperature:
37° C
Atmosphere:
5% CO2 in air
Storage medium:
Complete growth medium supplemented with 5% DMSO
Biosafety level:
1
References:
Helson et al. 1975. Cancer Research. 35(9):2594-2599. PMID:167965.
Biedler et al. 1978. Cancer research. 38:3751-3757. PMID: 29704.
Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.
